Industry News & Blogs
Lillie Shockney Receives "Amazing Nurses" Award from Johnson & Johnson - 12/12/2011
People within the Johns Hopkins community have long known that Lillie Shockney is an amazing nurse. Now she’s got the moniker to prove it. Shockney, administrative director of the Johns Hopkins Avon Breast Center since 1997, was selected as this year’s “Amazing Nurse” in a national contest to
Open Source May be the Answer for Pharma and Biotech | Xconomy
In his State of the Union Speech President Obama called for support for 'the same kind of research that led to the computer chip and the Internet.' He
Abbott Laboratories: An Attractively Valued Dividend Aristocrat - Seeking Alpha
< strong > By < a href='http://www.dividendgrowthinvestor.com' > Dividend Growth Investor < /a > : < /strong > < p > Abbott Laboratories ( < a href='http://seekingalpha.com/symbol/abt' title='Abbott Laboratories' > ABT < /a > ) engages in the discovery, development, manufacture, and sale of
Pharma Job Cuts | Pharma Employees Worry About Potential Job Cuts | Pharmaceutical Manufacturing
Forty-four percent of employees at major pharmaceutical companies are worried about losing their jobs this year, according to a new survey by the online community Pharma IQ.
Agilent, triple quadrupole GC/ | Agilent Technologies replaces signal-to-noise spec for triple
Agilent Technologies announced that it is replacing the signal-to-noise specification with a instrument detection limit specification for its 7000B triple quadrupole gas chromatography/mass spectrometry system.
Japan to become the next ‘hub’ for generic drugs market says new report | PRLog
Japan to become the next ‘hub’ for generic drugs market says new report. Piribo, the online destination for Pharma intelligence, has added a new report. - PR11799791
IsZo Capital Writes to Special Committee of Taro Pharmaceutical Demanding the Immediate Rejection
SYS-CON Media, NJ, The world's leading i-technology media company on breaking technology news.
GlaxoSmithKline Trying for Culture Shift and More
Coming out of 2011, GlaxoSmithKline hopes that it turned a corner, with leaders saying they hope several years of changes will result in higher and
Merck News Item
Merck & Co., Inc. home investors newsroom licensing careers contact us United States Canada MSD Worldwide About Us Our Values Be well Leadership How We Operate Views and Positions Our History Featured Stories Corporate Responsibility Research Pipeline Discovery & Development Products Vaccines
A STEPP too far for FLEX? – Authors' reply : The Lancet Oncology
A STEPP too far for FLEX? – Authors' reply. By - Robert Pirker, Stephan Störkel, Anja von Heydebreck, Ilhan Celik, Kenneth J O'Byrne
Refine by Topic:
- Drugs Registration (152)
- Generic Drugs (499)
- Medicine Production (1,084)
- Medicine Research & Development (5,152)
- Orphan Drugs (133)
Refine by Content Type:
Refine by Source:
- pharmtech.findpharma.com (3,454)
- www.biospace.com (1,019)
- seekingalpha.com (944)
- www.genengnews.com (540)
- www.dddmag.com (519)
- www.pharmaasia.com (518)
- www.prlog.org (480)
- www.pharmamanufacturing.com (441)
- www.pharmaceutical-business-review.com (402)
- www.thelancet.com (366)
- www.bioportfolio.co.uk (253)
- www.merck.com (242)

